Merck's Tulisokibart Shows Promise in Phase 2 Trial for Hidradenitis Suppurativa

Merck has announced positive Phase 2 data for its investigational humanized monoclonal antibody, tulisokibart, in patients with moderate to severe hidradenitis suppurativa (HS).

The trial met its primary endpoint of Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at week 16 for patients treated with both high-dose and medium-dose tulisokibart regimens, demonstrating superiority over placebo.

Specifically, 72% of patients in the high-dose group achieved HiSCR50, representing a 37% improvement over the placebo group, while 64% in the medium-dose group achieved HiSCR50, representing a 29% improvement over the placebo group.